DrugMapper


Trade Names:	ADRENACLICK ADRENALIN AUVI-Q BRONKAID MIST EPI E Z PEN JR EPINEPHRINE EPINEPHRINE (AUTOINJECTOR) EPIPEN EPIPEN E Z PEN EPIPEN JR. PRIMATENE MIST SUS-PHRINE SULFITE FREE SYMJEPI TWINJECT 0.15 TWINJECT 0.3
Synonyms:	Adrenaclick Adrenalin Adrenaline Adrenalinum Adren co Ana-guard Ana-Kit Anapen Anaphylactic shock drug kit Asma-vydrin Asthmahaler Auvi-q Bronkaid mist Brovon Emerade Epi e z pen jr (-)-epinephrine Epinephrine Epinephrine (copackaged) Epinephrine hcl Epinephrine hydrochloride Epinephrinum Epipen Epipen e z pen Epipen jr Epipen jr. Eppy Glauposine Gppe inh soln Jext L-epinephrine hydrochloride Levo-methylaminoethanolcatechol Medihaler-epi Nephridine NSC-62786 Primatene Primatene mist Racepinefrine, (r)- (-)-(r)-epinephrine Riddobron Riddofan Rybarvin Simplene Soln made to rybarvin for Susphrine Sus-Phrine Sus-phrine sulfite free Sus-Phrine Sulfite-Free Sus-phrine sulphite-free Symjepi Tonogen Twinject Twinject 0.15 Twinject 0.3
Status:	Approved (1965)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	A01AD01
UNII:	YKH834O4BH


InChI Key	UCTWMZQNUQWSLP-VIFPVBQESA-N
Smile	CNC[C@H](O)c1ccc(O)c(O)c1
InChI	InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1

Action	Mechanism of Action	Reference
AGONIST	Adrenergic receptor agonist	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor	15-436	17	630-631	200-14000	-
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Dopamine receptor	-	-	55000	910	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	-	29

Mesh Heading	Maximum Phase	Mesh ID	Reference
Hemorrhage	4	D006470	ClinicalTrials
Heart Arrest	4	D006323	ClinicalTrials
Pain	3	D010146	ClinicalTrials
Pulpitis	3	D011671	ClinicalTrials
Rhinitis, Allergic, Perennial	3	D012221	ClinicalTrials
Carcinoma, Non-Small-Cell Lung	3	D002289	ClinicalTrials
Bronchiolitis	3	D001988	ClinicalTrials
Gastrointestinal Hemorrhage	3	D006471	ClinicalTrials
Stomach Neoplasms	3	D013274	ClinicalTrials
Myoma	3	D009214	ClinicalTrials
Neoplasms	3	D009369	ClinicalTrials
Heart Failure	3	D006333	ClinicalTrials
Appendicitis	2	D001064	ClinicalTrials
Death, Sudden, Cardiac	2	D016757	ClinicalTrials
Wounds and Injuries	2	D014947	ClinicalTrials
Rotator Cuff Injuries	2	D000070636	ClinicalTrials
Hypospadias	2	D007021	ClinicalTrials
Cognitive Dysfunction	2	D060825	ClinicalTrials
Breast Neoplasms	2	D001943	ClinicalTrials
Osteoarthritis, Knee	2	D020370	ClinicalTrials
Hemoptysis	2	D006469	ClinicalTrials
Shock	2	D012769	ClinicalTrials
Ventricular Fibrillation	2	D014693	ClinicalTrials
Acute Lung Injury	2	D055371	ClinicalTrials
Tachycardia, Ventricular	2	D017180	ClinicalTrials
Infections	1	D007239	ClinicalTrials
Diabetes Mellitus	0	D003920	ClinicalTrials
Parathyroid Neoplasms	0	D010282	ClinicalTrials
Depressive Disorder	0	D003866	ClinicalTrials
Skin Neoplasms	0	D012878	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

Salt

Mixture

System Organ Classification (SOC)

	Relative Frequency (%)
Injury, poisoning and procedural complications	19.96
General disorders and administration site conditions	18.55
Cardiac disorders	9.79
Product issues	9.72
Vascular disorders	9.22
Nervous system disorders	5.66
Immune system disorders	5.18
Skin and subcutaneous tissue disorders	5.0
Investigations	3.83
Respiratory, thoracic and mediastinal disorders	3.73

EPINEPHRINE


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70